Fig. 2En-face and B scan optical coherence tomography angiography (OCTA) images of choriocapillaris of right eye at presentation (A1, A2) and 3 weeks after erlotinib treatment (B1, B2); Left eye at presentation (C1, C2) and 3 weeks following immunotherapy (D1, D2). Images representing central (A1, A2, B1, B2) and inferior (C1, C2, D1, D2) macula. Hyper-reflective choroidal nodules (white arrows, C2) with significant flow void in the choriocapillaris (A1, C1) suggestive of tumor infiltration. Three weeks after systemic erlotinib treatment, OCTA showing regression of choroidal lesions and resolution of flow voids in choriocapillaris (B1, B2, D1, D2). Scattered areas of flow void noted at presentation (red arrow, A1, C1) were largely replaced by flow signals (red arrowhead, B1, D1) not only in inferior macula where lesions were noted (C2) but also in central foveal area that no visible lesions were seen (compare arrowheads in A2 and B2). En-face images clearly indicate that vascular flow in choriocapillaris was restored to near normal post immunotherapy (B1, B2, D1, D2).